Nexgel, Inc · NASDAQ:NXGL
Nexgel — Investor Presentation (January 2024)
25 slides from Nexgel's investor presentation, Jan 31, 2024
Slide 1: NEXGEL Investor Presentation January 2024
@NEXCEL @ NEXGEL advanced hydrogel solutions Investor Present ion January 2024 iN / NASDAQ: NXGL \ i |
Slide 2: Forward-Looking Statement
Forward-Looking Statement This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and
Slide 3: NEXGEL - Who We Are and What We Do
NEXGEL - Who We Are and What We Do After two decades of creating custom hydrogel solutions for large medical device companies, NEXGEL has expanded its scope of business to include the development of our own patented medical devices, drug delivery systems, over-the-counter (OTC) healthcare consumer p
Slide 4: Competitive Advantage: State-of-the-Art Manufacturing Facilities in North America
Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments >1.4 Billion square inches 1 of 2 manufacturin
Slide 5: Hydrogels for Consumer and Medical Applications
Hydrogels for Consumer and Medical Applications oN * Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers * Gentle form
Slide 6: Multiple Shots on Goal for Growth
Multiple Shots on Goal for Growth Medical Custom & White Devices Label NEXGEL is Bringing proven addressing the medical-grade importance of technology to skin integrity OTC and Beauty & and overall Cosmetics for the skincare with a first time through medical device many new licensing model = consume
Slide 7: Multiple Aspirational Medical Device Opportunities
Multiple Aspirational Medical Device Opportunities y \ Addressing the importance of skin integrity and NN overall skincare with a medical device \ / / | » 4 | \ \ ONEXGEL NASDAQ: NXGL \ [\ y /| \ |
Slide 8: Medical Device Applications - Drug Delivery, NEXDrape & NEXDerm
Medical Device Applications - Drug Delivery, NEXDrape & NEXDerm Drug Delivery - Potential for drug delivery through unique hydrogels NEXDrape - A “skin friendly” solution for the surgical drape 510(k) market * Disrupting the rapidly growing surgical drape industry by providing consistent adhesion; g
Slide 9: Amblyopia Treatment
Amblyopia Treatment Amblyopia - type of poor vision that typically occurs in one eye, but can occur in both eyes (also referred to as lazy eye) Most common cause of visual impairment in childhood & affects approx. 2 to 3 children out of every 100 Global Amblyopia market expected to reach over $6 bil
Slide 10: Consumer Health & Beauty
Consumer Health & Beauty Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications NASDAQ: NXGL \ DY N \
Slide 11: Multiple Low-Risk Revenue Paths for Consumer Segment
Multiple Low-Risk Revenue Paths for Consumer Segment Research Development / Custom Label 6 —— PATCH CO.—~— IEXGEL your BEN-FREE NASDAQ; NXGL DTIC/ E-Commerce Proprietary Brands 1"
Slide 12: Custom & White Label Strategy
Custom & White Label Strategy NEXGEL leverages platform to supply OTC brands with unique, alo bovie gentle hydrogel-based products —= * All UV cured hydrogel patches contain AMP-acrylates/vinyl HAL=ON Isodecanoate crosspolymer, Toluene, and Vinyl acetate, or similar chemicals, which are non-starters
Slide 13: Supply Agreement with AbbVie
Supply Agreement with AbbVie (NYSE: ABBV) CG Converting and Packaging is exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite + Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic techn
Slide 14: Partnership with STADA Arzneimittel AG
Partnership with STADA Arzneimittel AG Signed December 2023, partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio + Mutually beneficial partnership to distribute and commercialize STADA consumer health OTC products in North America in 2024. + STADA a
Slide 15: Joint Venture with C.G. Laboratories
Joint Venture with C.G. Laboratories 50-50 ownership in converting and packaging business in Granbury, Texas + CG Labs current converting and packaging division is one of NEXGEL's largest customers for many years, revenue generating and already profitable * Transaction immediately increases converti
Slide 16: Proprietary Branded Products
Proprietary Branded Products Rapid growth since launch in Q4-2020 Medagel brand selling 11 SKUs on Amazon.com addressing: (3) Migraine Relief 2 Sports & Sports Related Applications General Podiatry Burn / Itch Relief 00 0 0 + Recently launched Turfguard, a unique dressing for soothing turf burn and
Slide 17: SilverSeal Anti-Microbial Data
SilverSeal® Anti-Microbial Data + SilverSeal® study was published SAGE Journals’ Scars, Burns and Healing publication. The results indicated that SilverSeal demonstrated statistically significant improvement of skin functionality, fewer negative symptoms, and a reduction of scar appearance relative
Slide 18: SilverSeal Opportunity
SilverSeal® Opportunity 40 patient double-blinded study data will allow NEXGEL to make a scar reduction claim Data has been submitted for peer review and publication 12 Weeks - Treated 12 Weeks - ra el Treated With With SilverSeal®" * SilverSeal® currently being sold for OTC wound Petroleum’ care on
Slide 19: Acquisition of Kenkoderm Skincare Line in December 2023
Acquisition of Kenkoderm Skincare Line in December 2023 Expands health and weliness consumer product portfolio with complimentary line of alternative treatments for psoriasis + Kenkoderm, for TTM, is profitable and expected to be immediately accretive + Synergies support optimization of marketing an
Slide 20: Capacity Expansion Underway to Fulfill Expected Growth
Capacity Expansion Underway to Fulfill Expected Growth 12,000 square foot expansion of Texas facility to support expected growth in product demand in 2024 is underway + Expansion will support the expected growth in product demand from its strategic partnerships with AbbVie and STADA, as well as reta
Slide 21: Financial Overview
Financial Overview
Slide 22: Revenue Growth with Scalable Infrastructure
Revenue Growth with Scalable Infrastructure Income Statement: + Record 2023 third quarter revenue: $1.22 million, +115% YOY + $2.3 million in revenue generated in Q3 and Q2 of '23, exceeded full year 2022 revenue + Contract manufacturing +182% YOY / branded consumer products +54% YOY + Gross profit
Slide 23: Growth Trends
Growth Trends Revenue Growth per Quarter $1,400 $1,200 Full Quarter Contribution of $1,000 CGlabs $800 seoo — $568K $400 $200 $0 $1.17M, — $4.227M, +108% YoY +115% YOY 032022. Q42022 © Q1 2023 , Q22023 =. Q3. 2023 Q2 & Q3 ‘23 Revenue of $2.3M, Exceeded 2022 Full Year Revenue o NASDAQ; NXGL 30.00% 20
Slide 24: Multiple Paths for Growth
Multiple Paths for Growth Scalable platform, strong cash position, and low cash needs for B2B expansion and online product sales enable multiple shots on goal with path to profitability in ‘24 Medical Devices Proprietary Branded Products White/ Custom Label Contract Manufacturing Market Multi-billio
Slide 25: Contact Us
Contact Us Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director NEXGEL@KCSA.com NASDAQ: NXGL | \ \ IN